|
1
|
Sanderson RJ and Ironside JA: Squamous
cell carcinomas of the head and neck. BMJ. 325:822–827. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stewart JS, Cohen EE, Licitra L, van
Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin
AM, Hirsch FR, et al: Phase III study of gefitinib compared with
intravenous methotrexate for recurrent squamous cell carcinoma of
the head and neck [corrected]. J Clin Oncol. 27:1864–1871. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermorken JB, Remenar E, van Herpen C,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al EORTC 24971/TAX 323 Study Group, : Cisplatin,
fluorouracil, and docetaxel in unresectable head and neck cancer. N
Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zöller M: CD44: Can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Major AG, Pitty LP and Farah CS: Cancer
stem cell markers in head and neck squamous cell carcinoma. Stem
Cells Int. 2013:3194892013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orian-Rousseau V: CD44, a therapeutic
target for metastasising tumours. Eur J Cancer. 46:1271–1277. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kajita M, Itoh Y, Chiba T, Mori H, Okada
A, Kinoh H and Seiki M: Membrane-type 1 matrix metalloproteinase
cleaves CD44 and promotes cell migration. J Cell Biol. 153:893–904.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HR, Wheeler MA, Wilson CM, Iida J, Eng
D, Simpson MA, McCarthy JB and Bullard KM: Hyaluronan facilitates
invasion of colon carcinoma cells in vitro via interaction with
CD44. Cancer Res. 64:4569–4576. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Golshani R, Lopez L, Estrella V, Kramer M,
Iida N and Lokeshwar VB: Hyaluronic acid synthase-1 expression
regulates bladder cancer growth, invasion, and angiogenesis through
CD44. Cancer Res. 68:483–491. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohkoshi E and Umemura N: Induced
overexpression of CD44 associated with resistance to apoptosis on
DNA damage response in human head and neck squamous cell carcinoma
cells. Int J Oncol. 50:387–395. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joshua B, Kaplan MJ, Doweck I, Pai R,
Weissman IL, Prince ME and Ailles LE: Frequency of cells expressing
CD44, a head and neck cancer stem cell marker: Correlation with
tumor aggressiveness. Head Neck. 34:42–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo B, Cao S, Tóth K, Azrak RG and Rustum
YM: Overexpression of Bax enhances antitumor activity of
chemotherapeutic agents in human head and neck squamous cell
carcinoma. Clin Cancer Res. 6:718–724. 2000.PubMed/NCBI
|
|
19
|
Stewart CF, Leggas M, Schuetz JD, Panetta
JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R,
Germain GS, et al: Gefitinib enhances the antitumor activity and
oral bioavailability of irinotecan in mice. Cancer Res.
64:7491–7499. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Azrak RG, Cao S, Durrani FA, Toth K,
Bhattacharya A and Rustum YM: Augmented therapeutic efficacy of
irinotecan is associated with enhanced drug accumulation. Cancer
Lett. 311:219–229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prahallad A, Sun C, Huang S, Di
Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A
and Bernards R: Unresponsiveness of colon cancer to BRAF(V600E)
inhibition through feedback activation of EGFR. Nature.
483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kokko LL, Hurme S, Maula SM, Alanen K,
Grénman R, Kinnunen I and Ventelä S: Significance of site-specific
prognosis of cancer stem cell marker CD44 in head and neck
squamous-cell carcinoma. Oral Oncol. 47:510–516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qin D, Gan Y, Shao K, Wang H, Li W, Wang
T, He W, Xu J, Zhang Y, Kou Z, et al: Mouse meningiocytes express
Sox2 and yield high efficiency of chimeras after nuclear
reprogramming with exogenous factors. J Biol Chem. 283:33730–33735.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ang YS, Tsai SY, Lee DF, Monk J, Su J,
Ratnakumar K, Ding J, Ge Y, Darr H, Chang B, et al: Wdr5 mediates
self-renewal and reprogramming via the embryonic stem cell core
transcriptional network. Cell. 145:183–197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:pp. 973–978. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Faber A, Barth C, Hörmann K, Kassner S,
Schultz JD, Sommer U, Stern-Straeter J, Thorn C and Goessler UR:
CD44 as a stem cell marker in head and neck squamous cell
carcinoma. Oncol Rep. 26:321–326. 2011.PubMed/NCBI
|
|
27
|
Giancotti FG: Mechanisms governing
metastatic dormancy and reactivation. Cell. 155:750–764. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cohen EE, Kane MA, List MA, Brockstein BE,
Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A and Vokes EE: Phase
II trial of gefitinib 250 mg daily in patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck.
Clin Cancer Res. 11:8418–8424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haakenson JK, Khokhlatchev AV, Choi YJ,
Linton SS, Zhang P, Zaki PM, Fu C, Cooper TK, Manni A, Zhu J, et
al: Lysosomal degradation of CD44 mediates ceramide
nanoliposome-induced anoikis and diminished extravasation in
metastatic carcinoma cells. J Biol Chem. 290:8632–8643. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chinn SB, Darr OA, Owen JH, Bellile E,
McHugh JB, Spector ME, Papagerakis SM, Chepeha DB, Bradford CR,
Carey TE, et al: Cancer stem cells: Mediators of tumorigenesis and
metastasis in head and neck squamous cell carcinoma. Head Neck.
37:317–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oliveira LR, Castilho-Fernandes A,
Oliveira-Costa JP, Soares FA, Zucoloto S and Ribeiro-Silva A:
CD44+/CD133+ immunophenotype and matrix metalloproteinase-9:
Influence on prognosis in early-stage oral squamous cell carcinoma.
Head Neck. 36:1718–1726. 2014. View Article : Google Scholar : PubMed/NCBI
|
